Stability Studies SOP

The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for documenting stability studies for New Drug Applications (NDAs) to the United States Food and Drug Administration (US FDA). This SOP ensures that stability data is presented in a manner consistent with US FDA regulatory requirements to support product approval.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for preparing stability study reports for Abbreviated New Drug Application (ANDA) submissions to the United States Food and Drug Administration (US FDA). This SOP ensures that stability data is presented in a manner that meets regulatory requirements and supports product approval.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for conducting stability testing of new dosage forms in accordance with the ICH Q1C guidelines. This SOP ensures that the stability data generated supports the quality, safety, and efficacy of new dosage forms throughout their shelf life.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting stability testing for post-approval changes to drug substances and products in accordance with US FDA guidelines. This SOP ensures that any changes made after approval do not adversely affect the product’s quality, safety, or efficacy.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for conducting stability studies for drug substances and drug products in accordance with the Pharmaceutical and Medical Device Agency (PMDA) of Japan. This SOP ensures that the stability data generated meets Japanese regulatory standards and supports the quality, safety, and efficacy of pharmaceutical products throughout their shelf life.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for conducting stability testing of drug products intended for export in accordance with the ICH Q1F guidelines. This SOP ensures that stability data generated meets the requirements of different climatic zones to which the products are exported.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for designing stability studies for combination products in accordance with relevant regulatory guidelines. This SOP ensures that stability studies provide adequate data to support the quality, safety, and efficacy of combination products.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to provide a procedure for conducting stability studies of modified release drug products in accordance with US FDA and ICH guidelines. This SOP ensures that the stability data generated is suitable for supporting product quality, safety, and efficacy throughout its shelf life.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for reporting stability data in the Common Technical Document (CTD) format for regulatory submissions. This SOP ensures that stability data is presented in a standardized manner that meets global regulatory requirements.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for conducting stability testing of drug products in accordance with the ASEAN (Association of Southeast Asian Nations) guidelines. This SOP ensures that stability data generated is adequate to support the quality, safety, and efficacy of products throughout their shelf life under ASEAN regulatory standards.
Click to read the full article.